Items Tagged ‘EAH’

June 23rd, 2016

Blincyto® Improves Survival in Type of Acute Lymphoblastic Leukemia


The immunotherapeutic agent, Blincyto (blinatumomab), improves survival compared to standard therapy among patients with B-cell precursor, Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (BCP-ALL) that has stopped responding to prior therapies. These results were presented at a presidential symposium at the 2016 annual European Hematologic Association (EHA) meeting. Acute lymphoblastic leukemia (ALL) is the most aggressive […]

View full entry

Tags: 2016, Acute Lymphoblastic Leukemia, all, BCP-ALL, blinatumomab, blincyto, EAH, Leukemia, News, TOWER trial